Natural History of Wilson Disease
Natural History of Wilson Disease: Registry for Patients With Wilson Disease
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
There are three aims outlined as part of this research study.
Aim 1 is to study the natural history of a carefully characterized cohort of patients with WD followed longitudinally at Centers of Excellence for WD in the United States and in the United Kingdom.
Aim 2 seeks to evaluate parameters for diagnosis and treatment monitoring for patients on chelation therapy and zinc treatment for their WD. Data gathered in Specific aim 1 will be used for analyzing the components of the diagnostic scores for patients.
Aim 3 is intended to determine whether a composite index or a biomarker can be used as surrogate marker for treatment monitoring for current patients on therapy that can be used for future patient treatment trials.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ricarda Tomlin
- Phone Number: (203) 785-2073
- Email: ricarda.tomlin@yale.edu
Study Contact Backup
- Name: Sefa Keserci, PhD
- Phone Number: (203) 3766043
- Email: sefa.keserci@yale.edu
Study Locations
-
-
-
Heidelberg, Germany, 69120
- Recruiting
- Universitätsklinikum Heidelberg
-
Contact:
- Jessica Langel
- Phone Number: +49 6221 56-32512
- Email: jessica.langel@med.uni-heidelberg.de
-
Contact:
- Andrea Langel
- Email: andrea.langel@med.uni-heidelberg.de
-
Principal Investigator:
- Isabelle Mohr, MD
-
-
-
-
Surrey
-
Guildford, Surrey, United Kingdom, GU2
- Recruiting
- Royal Surrey Country Hospital
-
Contact:
- Michelle Camarata, MD
- Email: michelle.camarata@yale.edu
-
Contact:
- Joanna Smith
- Phone Number: 4088 01487571122
- Email: joanna.smith64@nhs.net
-
Principal Investigator:
- Aftab Ala, MD
-
-
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Recruiting
- Yale University
-
Principal Investigator:
- Michael Schilsky, MD
-
Contact:
- Sefa Keserci, PhD
- Phone Number: 203-376-6043
- Email: sefa.keserci@yale.edu
-
Contact:
- Asim Ulcay
- Email: asim.ulcay@yale.edu
-
-
Florida
-
Orlando, Florida, United States, 32803
- Recruiting
- Advent Health
-
Contact:
- Ariana Mora
- Email: Ariana.Mora@AdventHealth.com
-
Contact:
- Pamela Hedrick
- Email: Pamela.Hedrick@AdventHealth.com
-
Principal Investigator:
- Regino Gonzalez-Peralta, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Baylor College of Medicine
-
Contact:
- Reza Amerinia
- Email: reza.amerinia@bcm.edu
-
Principal Investigator:
- Sanjiv Harpavat, MD
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Seattle Children's Hospital
-
Contact:
- Phi Duong
- Email: phi.duong@seattlechildrens.org
-
Principal Investigator:
- Sihoun Hahn, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Known diagnosis of WD
- Able and willing to provide informed consent for adults (Parental/guardian permission (informed consent) and if appropriate, child assent for participants <18 (or per local Institutional Review Board (IRB) regulation)
Exclusion Criteria:
- Diagnosis of WD has been excluded
- Unwilling to provide informed consent or assent
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Create registry for Wilson disease
Time Frame: 5 Years
|
This outcome is a binary 'yes/no' outcome as to whether or not this study can successfully create a repository with the intent to store data and specimens to support the conduct of future research on Wilson disease.
|
5 Years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Digestive System Diseases
- Neurodegenerative Diseases
- Liver Diseases
- Movement Disorders
- Heredodegenerative Disorders, Nervous System
- Basal Ganglia Diseases
- Brain Diseases, Metabolic, Inborn
- Brain Diseases, Metabolic
- Metal Metabolism, Inborn Errors
- Hepatolenticular Degeneration
Other Study ID Numbers
Other Study ID Numbers
- 1609018429
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wilson Disease
-
NCT07476417Not yet recruitingPeriodontal Diseases | Dental Caries | Tooth Diseases | Malocclusion | Craniofacial Abnormalities | Tooth Abnormalities | Oral Mucosal Disease | Oral Health Related Quality of Life (OHRQoL) | Sleep Related Breathing Disorder | Mowat-Wilson Syndrome
-
NCT05792319Not yet recruitingClinical Outcome in WILSON Disease
-
NCT06196931Not yet recruitingHepatolenticular Degeneration; Wilson
-
NCT05917327Terminated
-
NCT07226622Active, not recruiting
-
NCT07159581Enrolling by invitationWilson Disease
-
NCT07173933Not yet recruiting
-
NCT07301216Recruiting
-
NCT00212355Completed